Patricia Mae G Santos, Manisha Dubey, Haley Simpson, Arthur S Hong, Aman Narayan, Sonia Persaud, Katherine Feldman, Emily Anderson, Jennifer Santos, Melina Smith, Monica F Bryant, Joanna F Doran, Mylin A Torres, Lilia Cervantes, K Robin Yabroff, Fumiko Chino
{"title":"Access to cancer care for undocumented immigrants in the USA","authors":"Patricia Mae G Santos, Manisha Dubey, Haley Simpson, Arthur S Hong, Aman Narayan, Sonia Persaud, Katherine Feldman, Emily Anderson, Jennifer Santos, Melina Smith, Monica F Bryant, Joanna F Doran, Mylin A Torres, Lilia Cervantes, K Robin Yabroff, Fumiko Chino","doi":"10.1016/s1470-2045(25)00207-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00207-4","url":null,"abstract":"Undocumented immigrants face substantial barriers to affordable health-care coverage in the USA. For people with cancer, federal restrictions on publicly funded health insurance pose serious downstream consequences, including delayed diagnosis, scarce treatment options, and worse health outcomes. In this Policy Review, we examine mechanisms through which undocumented immigrants access cancer care in the USA, focusing on Emergency Medicaid, Medicaid-equivalent plans, and Marketplace-based strategies. We evaluate the strengths and limitations of these approaches, highlighting how each can shape access to cancer prevention, diagnosis, treatment, and follow-up care. We offer insights in regard to the 2025 US presidential administration for states that seek to protect or expand access to cancer care for undocumented immigrants in a challenging sociopolitical climate. The goal of this Policy Review is to guide the creation of innovative policy solutions to mitigate geographical disparities in the hope of improving cancer outcomes for this underserved population.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"90 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Epithelioid sarcoma presenting as a progressively enlarging wound","authors":"Yu-Ting Tsai, Jui Lan, Yi-Chien Yang","doi":"10.1016/s1470-2045(25)00378-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00378-x","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributors</h2>All authors contributed substantially to the collection of data and drafting of this manuscript, and approved the final version. Written informed consent to publication was obtained.</section></section><section><section><h2>Declaration of interests</h2>We declare no competing interests.</section></section>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leonardo Quarta, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi
{"title":"Reflections on the PEACE V–STORM trial","authors":"Leonardo Quarta, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi","doi":"10.1016/s1470-2045(25)00347-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00347-x","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The fight against burnout: doctors in distress","authors":"Paul Efthymiou, Susannah Basile","doi":"10.1016/s1470-2045(25)00131-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00131-7","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>From a tragedy to creating a charity</h2>“I've just started a charity. I want to prevent this from happening again.” These poignant words were shared by Amandip Sidhu during a <span><span>podcast</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> interview reflecting on the tragic death of his brother, Dr Jagdip Sidhu, a consultant cardiologist who died by suicide in November 2018 after enduring severe burnout. From this profound personal loss emerged Doctors in Distress, a UK-based independent charity dedicated to promoting wellbeing and preventing burnout and suicide among NHS health-care</section></section><section><section><h2>Oncology: a unique set of challenges</h2>In oncology, the emotional stakes are extraordinarily high. Oncologists and cancer care teams confront not only the complexities of treatment but also the profound personal toll of guiding patients through terminal diagnoses and end-of-life care. This constant exposure to loss and grief contributes substantially to burnout and compassion fatigue—a unique challenge that demands tailored support.</section></section><section><section><h2>A crisis in burnout: evidence from Europe</h2>The report, <em>Under Pressure: Safeguarding the Health of Europe's Oncology Workforce</em>, published by the European Cancer Organisation in 2024, highlighted a stark reality. From a study sample of more than 700 individuals across 30 countries in Europe, 19% of health-care professionals involved in cancer care reported high levels of burnout, and 30% frequently experienced anxiety due to work pressures. More than half of the participants said their supervisors do not care about their wellbeing,</section></section><section><section><h2>The cost of burnout: a sobering toll</h2>The consequences of burnout are devastating. In the UK, statistics suggest that a nurse dies by suicide every week and a doctor takes their life every 3 weeks. During the COVID-19 pandemic, the demand for support from Doctors in Distress and mental health services surged. In 2022, 366 nurses in the UK attempted suicide, which was a 62% increase from the previous year.The pressure on general practitioners is similarly alarming. As of November, 2024, 1391 general practices in the UK had closed</section></section><section><section><h2>Tackling burnout: solutions through support and prevention</h2>Although the data paint a clear picture of the problem, they do little to provide a solution or alleviate the suffering of those affected. This underscores the vital role of organisations like Doctors in Distress.The charity has supported over 4000 health-care workers through free weekly peer-to-peer support groups. Facilitated by professionals from a range of backgrounds, including psychoanalysts and psychotherapists, these groups provid","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Raoull Hoogendijk, Riccardo Capocaccia, Jasper van der Lugt, Mariëtte E G Kranendonk, Eelco W Hoving, Pieter Wesseling, Otto Visser, Dannis G van Vuurden, Gemma Gatta, Henrike E Karim-Kos
{"title":"Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study","authors":"Raoull Hoogendijk, Riccardo Capocaccia, Jasper van der Lugt, Mariëtte E G Kranendonk, Eelco W Hoving, Pieter Wesseling, Otto Visser, Dannis G van Vuurden, Gemma Gatta, Henrike E Karim-Kos","doi":"10.1016/s1470-2045(25)00297-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00297-9","url":null,"abstract":"<h3>Background</h3>Clinically relevant survival outcomes, including cure fraction estimates, and long-term survival outcomes of paediatric CNS tumours from large-scale databases have not been reported for Europe. Moreover, various biases hinder direct geographical comparisons, thereby limiting the effective translation of population-based findings into cancer care, surveillance, and research. We aimed to estimate these survival outcomes across Europe through the EUROCARE database.<h3>Methods</h3>In this population-based study, we analysed survival data from the EUROCARE-6 database from children younger than 15 years with a CNS tumour across 31 European countries. For the period 2008–13, we estimated observed survival via the actuarial method, and 5-year observed survival was reported at the European level and national level for four major CNS tumour groups. For the period 1998–2013, cure fraction was estimated through a mixture cure model assuming constant long-term mortality from other causes. Additionally, model-based 10-year and 15-year survival were estimated.<h3>Findings</h3>For observed survival analyses, 13 782 tumour cases were included. 5-year observed survival was 72% (95% CI 68 to 75) for ependymomas, 92% (91 to 93) for low-grade gliomas, 47% (45 to 49) for high-grade gliomas, 24% (21 to 27) for high-grade gliomas excluding glioma not otherwise specified, and 64% (62 to 67) for medulloblastomas. A total of 30 392 children were included in the cure fraction analysis. During the study period, the largest absolute increase in cure fraction was observed for ependymomas from 65% (57 to 73) in 1998–2001 to 79% (69 to 89) in 2010–13, whereas low-grade gliomas increased from from 89% (85 to 94) to 95% (89 to 100), high-grade gliomas had a 6 percentage point change increase (2 to 10), and medulloblastomas increased from 52% (49 to 55) to 56% (51 to 60). The estimated 10-year and 15-year survival rates were highest for low-grade gliomas at 90·6% (89·4 to 91·7) at 10 years and 88·5% (87·2 to 89·8) at 15 years, whereas the lowest survival rates were observed for high-grade gliomas excluding glioma not otherwise specified at 20·5% (17·0 to 24·1) and 19·0% (15·6 to 22·5).<h3>Interpretation</h3>This study is the first to report a comprehensive evaluation of survival parameters for paediatric CNS tumour patients in Europe. These outcomes are important to evaluate advances in care for children with a CNS tumour.<h3>Funding</h3>Princess Máxima Center for Pediatric Oncology and Associazione Italiana per la Ricerca sul Cancro.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shafak Aluwini, Ruth van der Walle, Walter Noordzij
{"title":"Reflections on the PEACE V–STORM trial","authors":"Shafak Aluwini, Ruth van der Walle, Walter Noordzij","doi":"10.1016/s1470-2045(25)00365-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00365-1","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}